Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Berger JR, et al. Among authors: gold r. Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. Ann Neurol. 2010. PMID: 20818795 No abstract available.
Towards individualised multiple-sclerosis therapy.
Gold R, Hartung HP. Gold R, et al. Lancet Neurol. 2005 Nov;4(11):693-4. doi: 10.1016/S1474-4422(05)70205-2. Lancet Neurol. 2005. PMID: 16239174 No abstract available.
Type III systemic allergic reaction to natalizumab.
Leussink VI, Lehmann HC, Hartung HP, Gold R, Kieseier BC. Leussink VI, et al. Among authors: gold r. Arch Neurol. 2008 Jun;65(6):851-2; author reply 852. doi: 10.1001/archneur.65.6.851-b. Arch Neurol. 2008. PMID: 18541818 No abstract available.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Kappos L, et al. Among authors: gold r. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Lancet. 2008. PMID: 18970976 Clinical Trial.
2,055 results